The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000116820
Ethics application status
Approved
Date submitted
24/01/2012
Date registered
24/01/2012
Date last updated
15/03/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of ocular response and subjective comfort ratings in forty participants with Clariti TradeMark 1day daily disposable contact lens wear for three months
Scientific title
Prospective, open label, single group study where a minimum of 40 myopic participants will wear Clariti TradeMark 1day contact lenses bilaterally on a daily disposable basis for a total of three months to evaluate ocular response and subjective comfort ratings
Secondary ID [1] 279775 0
Nil
Universal Trial Number (UTN)
U1111-1127-4301
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ocular comfort/discomfort 285659 0
Ocular response to contact lens wear 285662 0
Condition category
Condition code
Eye 285837 285837 0 0
Normal eye development and function

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Clariti TradeMark 1day contact lenses will be worn on a daily wear, single use basis for a minimum of 5 days per week, at least 6 hours per day (no overnight wear) for a duration of 3 months. Clariti TradeMark 1day contact lenses are made of Filcon II 3 material
Intervention code [1] 284100 0
Treatment: Devices
Comparator / control treatment
Nil
Control group
Uncontrolled

Outcomes
Primary outcome [1] 286345 0
Ocular response including ocular redness, corneal and conjunctival fluorescein staining
Timepoint [1] 286345 0
Measured at Baseline, 2 Hour after Baseline, 2 weeks after Baseline, 1 Month after Baseline and 3 Months after Baseline. It may also be measured at any unscheduled visits during the trial.
Primary outcome [2] 286346 0
Subjective comfort ratings measured with a Numeric Rating Scale of 1 to 10.
Timepoint [2] 286346 0
Measured at Baseline, 2 Hour after Baseline, 2 weeks after Baseline, 1 Month after Baseline and 3 Months after Baseline. It may also be measured at any unscheduled visits during the trial.
Secondary outcome [1] 295640 0
Nil
Timepoint [1] 295640 0
Nil

Eligibility
Key inclusion criteria
Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
Be at least 18 years old, male or female.
Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
Have ocular health findings considered to be “normal” and which would not prevent the participant from safely wearing contact lenses.
Is myopic and correctable to at least 6/12 (20/40) or better in each eye with contact lenses.
Be experienced or inexperienced at wearing contact lenses.
Be able to insert and remove contact lenses, after tuition if required.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
N.B.: Systemic antihistamines are allowed on an “as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is first used.
Eye surgery within 12 weeks immediately prior to enrolment for this trial.
Previous corneal refractive surgery.
Contraindications to contact lens wear.
Known allergy or intolerance to ingredients in any of the clinical trial products.
Currently enrolled in another clinical trial.
Participation in a clinical trial within the previous 2 weeks for dispensing studies and 48 hours between in-house studies.
Pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
open
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 284559 0
Charities/Societies/Foundations
Name [1] 284559 0
Brien Holden Vision Institute
Address [1] 284559 0
Level 5 North Wing Rupert Myers Building, Gate 14 Barker Street, University of New South Wales Sydney NSW 2052
Country [1] 284559 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Brien Holden Vision Institute
Address
Level 5 North Wing Rupert Myers Building, Gate 14 Barker Street, University of New South Wales Sydney NSW 2052
Country
Australia
Secondary sponsor category [1] 283481 0
None
Name [1] 283481 0
Address [1] 283481 0
Country [1] 283481 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 286542 0
Bellberry Human Research Ethics Committee
Ethics committee address [1] 286542 0
229 Greenhill Road,
Dulwich,
South Australia 5065
Ethics committee country [1] 286542 0
Australia
Date submitted for ethics approval [1] 286542 0
16/12/2011
Approval date [1] 286542 0
Ethics approval number [1] 286542 0
2011-12-586

Summary
Brief summary
Clariti TradeMark 1day by Sauflon Pharmaceuticals is one of the new silicone hydrogel daily disposable lenses recently released into the contact lens market. This study intends to provide more information on the clinical performance of Clariti TradeMark 1 Day in terms of ocular health, vision and subjective comfort. It will allow for comparisons to previous and future contact lens related studies in the hope that it can contribute to further understanding on what causes contact lens related discomfort and dryness. The hypothesis of this study is that the ocular responses and subjective comfort ratings will be dissimilar in participants wearing Clariti TradeMark 1 Day and other lens types.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33666 0
Address 33666 0
Country 33666 0
Phone 33666 0
Fax 33666 0
Email 33666 0
Contact person for public queries
Name 16913 0
Jennie Diec
Address 16913 0
Level 5, North Wing
Rupert Myers Building
Gate 14, Barker Street
UNSW Sydney NSW 2052
Country 16913 0
Australia
Phone 16913 0
+612 9385 7516
Fax 16913 0
+612 9385 7401
Email 16913 0
j.diec@brienholdenvision.org
Contact person for scientific queries
Name 7841 0
Jennie Diec
Address 7841 0
Level 5, North Wing
Rupert Myers Building
Gate 14, Barker Street
UNSW Sydney NSW 2052
Country 7841 0
Australia
Phone 7841 0
+61 2 9385 7516
Fax 7841 0
+612 9385 7401
Email 7841 0
j.diec@brienholdenvision.org

No information has been provided regarding IPD availability
Summary results
No Results